1. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines

   • Xing Chen
   • Dongsheng Xiong
   • Ruoran Mi

   Original Article 09 January 2019 Pages: 603 - 613

   

2. Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma

   • Xiaoxia Zhu
   • Xiaohua Tao
   • Yi Tang

   Original Article 09 January 2019 Pages: 615 - 624

   

3. Upregulation of MTA1 expression by human papillomavirus infection promotes CDDP resistance in cervical cancer cells via modulation of NF-κB/APOBEC3B cascade

   • Qiu-ping Jia
   • Chang-you Yan
   • Lei Cao

   Original Article 10 January 2019 Pages: 625 - 637

   

4. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study

   • Lei Gong
   • Weimin Mao
   • Yun Fan

   Original Article 14 January 2019 Pages: 639 - 647

   

5. Encapsulation of a new quinoxaline derivative in PLGA alters the pattern of its anticancer potency and induces apoptosis

   • Entsar A. Saad
   • Heba M. Waly

   Original Article 16 January 2019 Pages: 649 - 658

   

6. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate

   • Yoriko Yamashita-Kashima
   • Yasushi Yoshimura
   • Naoki Harada

   Original Article 18 January 2019 Pages: 659 - 671

   

7. Influence of oral magnesium-containing supplement and antacid administration on hypomagnesemia induced by panitumumab

   • Junya Sato
   • Hiroshi Ishikawa
   • Michihiro Sino

   Original Article 19 January 2019 Pages: 673 - 679

   

8. In vitro and in vivo anticancer effects of two quinoline–platinum(II) complexes on human osteosarcoma models

   • Maria Carolina Ruiz
   • Agustina Resasco
   • Ignacio Esteban León

   Original Article 19 January 2019 Pages: 681 - 692

   

9. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia

   • Hannah Yejin Kim
   • Janna K. Duong
   • Alan V. Boddy

   Original Article 19 January 2019 Pages: 693 - 704

   

10. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers

    • Mayu Osawa
    • Mayumi Hasegawa
    • Matthew W. Hruska

    Original Article Open access 21 January 2019 Pages: 705 - 715

    

11. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer

    • Kathleen Moore
    • John K. Chan
    • Zhi-Yi Zhang

    Original Article 24 January 2019 Pages: 717 - 726

    

12. Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel

    • Lin Guo
    • Hao Peng
    • Jin-An Ma

    Original Article 24 January 2019 Pages: 727 - 734

    

13. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer

    • Osman Köstek
    • Erdem Yılmaz
    • Bülent Erdoğan

    Original Article 24 January 2019 Pages: 735 - 742

    

14. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer

    • M. Campone
    • T. Bachelot
    • F. Andre

    Original Article Open access 25 January 2019 Pages: 743 - 753

    

15. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia

    • Al-Motassem Yousef
    • Rand Farhad
    • Taha Kadi

    Original Article 25 January 2019 Pages: 755 - 762

16. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer

    • Alexander Hoemme
    • Holger Barth
    • Markus Joerger

    Original Article 25 January 2019 Pages: 763 - 774

    

17. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

    • E. Baudry
    • S. Huguet
    • Keyvan Rezai

    Original Article 28 January 2019 Pages: 775 - 785

    

18. Phase I study of orally administered ¹⁴Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies

    • Alexander MacDonald
    • Graeme Scarfe
    • Emma Dean

    Original Article 13 February 2019 Pages: 787 - 795

    

19. d-dimer increase: an unfavorable factor for patients with primary liver cancer treated with TACE

    • Xujiao Chen
    • Zhihui Chang
    • Zhaoyu Liu

    Original Article 13 February 2019 Pages: 797 - 802

    

20. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study

    • Beatrice De Troia
    • Davide Dalu
    • Maria Teresa Cattaneo

    Short Communication 22 February 2019 Pages: 803 - 808